Case report from a study investigating everolimus combined with paclitaxel and carboplatin in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC)
M Steins, W Engel-Riedel, C Grohé, C Kropf-Sanchen, J von Pawel, S Gütz, J Kollmeier, W Eberhardt, D Ukena, I Nimmrich, C Weiß, M Potzner, M Serke, M Thomas · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Targeted therapies are discussed as an approach to improve outcome in neuroendocrine tumors of the lung. With current treatment options like platinum derivates and etoposide, large cell neuroendocrine carcinoma of the lung (LCNEC) patients have a poor prognosis. Everolimus (RAD001) is an inhibitor of mTOR, a component of the PI3K/AKT/mTOR pathway known to be dysregulated in neuroendocrine tumors (NETs). In the presented trial for advanced LCNEC patients, daily RAD001 is combined in first-line with carboplatin and paclitaxel, a standard chemotherapy for this population. Enrolled patients receive 4 cycles of combi…
